Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG) Pernilla Dahm-Kähler a,d, ⁎, Christer Borgfeldt b , Erik Holmberg c,d , Christian Staf c , Henrik Falconer e , Maria Bjurberg f , Preben Kjölhede g , Per Rosenberg h , Karin Stålberg i , Thomas Högberg j , Elisabeth Åvall-Lundqvist k,l a Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden b Department of Obstetrics and Gynecology, Skane University Hospital, Lund University, Lund, Sweden c Regional Cancer Center Western Sweden, Sahlgrenska University Hospital, Gothenburg, Sweden d Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden e Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden f Department of Clinical Sciences, Skane University Hospital, Lund, Sweden g Department of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden h Department of Oncology, University Hospital Linköping, Linköping, Sweden i Department of Women's and Children's health Uppsala University, Uppsala, Sweden j Department of Cancer Epidemiology, Lund University, Lund, Sweden k Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden l Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden HIGHLIGHTS • Poor patient survival for non-uterine serous cancer at undesignated primary site • Further studies needed to explore reasons for non-surgical treatment of serous cancer. • International standardized criteria for primary site assignment of serous cancer needed • Serous cancer of undesignated site should be included when reporting survival rates. abstract article info Article history: Received 30 August 2016 Received in revised form 19 October 2016 Accepted 24 October 2016 Available online xxxx Objective. The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. Methods. Nation-wide population-based study of women ≥ 18 years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peri- toneum diagnosed 2009–2013. Relative survival (RS) was estimated using the Ederer II method. Simple and mul- tivariable analyses were estimated by Poisson regression models. Results. Of 5627 women identified, 1246 (22%) had borderline tumors and 4381 had malignant tumors. In total, 2359 women had serous cancer; 71% originated in the ovary (OC), 9% in the fallopian tube (FTC), 9% in the peritoneum (PPC) and 11% at an undesignated primary site (UPS). Estimated RS at 5-years was 37%; for FTC 54%, 40% for OC, 34% for PPC and 13% for UPS. In multivariable regression analyses restricted to women who had undergone primary or interval debulking surgery for OC, FTC and PPC, site of origin was not indepen- dently associated with survival. Significant associations with worse survival were found for advanced stages (RR 2.63, P b 0.001), moderate (RR 1.90, P b 0.047) and poor differentiation (RR 2.20, P b 0.009), neoadjuvant che- motherapy (RR1.33, P b 0.022), residual tumor (RR 2.65, P b 0.001) and platinum single (2.34, P b 0.001) com- pared to platinum combination chemotherapy. Keywords: Ovarian cancer Serous cancer Survival Cancer origin Gynecologic Oncology xxx (2016) xxx–xxx ⁎ Corresponding author at: Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, SE-41345 Gothenburg, Sweden. E-mail address: pernilla.dahm-kahler@vgregion.se (P. Dahm-Kähler). YGYNO-976513; No. of pages: 7; 4C: 5, 6 http://dx.doi.org/10.1016/j.ygyno.2016.10.039 0090-8258/© 2016 Elsevier Inc. All rights reserved. Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Please cite this article as: P. Dahm-Kähler, et al., Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin ..., Gynecol Oncol (2016), http://dx.doi.org/10.1016/j.ygyno.2016.10.039